RxDoctor Payments Data

Christy Odonnell

Family · Stamford, NYNPI 1831202183

Payments from drug & device makers

$1,461in general payments, 2019–2025

Across 72 payments — averaging $20.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$393
  • Pfizer$293
  • AbbVie$208
  • GSK$132
  • Exact Sciences$105
  • Lilly USA, LLC$74
  • plus $256 from 8 others

What the payments were for

  • Food & beverage$1,461100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,461 in reported general payments places this provider in the 75th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$82,854
Medicare patients
332
Services billed
1,261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide58$124,025
EliquisApixaban66$87,721
JardianceEmpagliflozin68$87,365
TrulicityDulaglutide15$32,841
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$22,823
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$21,831
FarxigaDapagliflozin Propanediol15$18,688
JanuviaSitagliptin Phosphate13$15,866
Spiriva HandihalerTiotropium Bromide17$11,858
Breo ElliptaFluticasone/Vilanterol11$11,236
SymbicortBudesonide/Formoterol Fumarate13$4,498
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$4,388
Albuterol Sulfate HfaAlbuterol Sulfate72$4,343
Varenicline Tartrate17$4,207
Atorvastatin Calcium392$4,163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$48$124,02558 claims
PfizerEliquis$293$87,72166 claims
Boehringer IngelheimJardiance$16$87,36568 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$132$55,89070 claims
Lilly USA, LLCTrulicity$74$32,84115 claims
AstraZenecaFarxiga, Symbicort$393$23,18528 claims
AbbVieSynthroid$208$3,83293 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,883 family providers in New York.

Other family in Stamford

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →